26.68

0.37% -0.10

After Hours: 26.68

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $26.68, with a volume of 412.70K. It is down -0.37% in the last 24 hours and up +3.41% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$26.78

Open:

$27.02

24h Volume:

412.70K

Relative Volume:

0.66

Market Cap:

$1.98B

Revenue:

$105.97M

Net Income/Loss:

$-81.13M

P/E Ratio:

-24.72

EPS:

-1.0791

Net Cash Flow:

$-35.43M

1W Performance:

-4.51%

1M Performance:

+3.41%

6M Performance:

+47.81%

1Y Performance:

+107.63%

1-Day Range:

$26.12

$27.33

1-Week Range:

$26.12

$28.18

52-Week Range:

$10.86

$29.75

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2026-05-07

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	26.68	1.99B	105.97M	-81.13M	-35.43M	-1.0791
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform
Oct-24-25	Resumed	Wells Fargo	Equal Weight
Oct-14-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

05:35 AM

Pictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYME - MarketBeat

05:35 AM

May 03, 2026

Kornitzer Capital Management Inc. KS Takes $2.34 Million Position in Zymeworks Inc. $ZYME - MarketBeat

May 03, 2026

Apr 28, 2026

H.C. Wainwright reiterates Zymeworks stock rating on FDA filing By Investing.com - Investing.com India

Apr 28, 2026

Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 28, 2026

H.C. Wainwright reiterates Zymeworks stock rating on FDA filing - Investing.com UK

Apr 28, 2026

Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera - Yahoo Finance

Apr 26, 2026

Apr 23, 2026

Zymeworks stock hits 52-week high at $28.50 By Investing.com - Investing.com India

Apr 23, 2026

Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 23, 2026

Apr 22, 2026

Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighWhat's Next? - MarketBeat

Apr 22, 2026

Zymeworks stock hits 52-week high at $28.50 - Investing.com

Apr 22, 2026

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 - wahanariau.com

Apr 22, 2026

Stifel reiterates Zymeworks stock rating on ADC data strength - Investing.com UK

Apr 22, 2026

Apr 21, 2026

Zymeworks reports phase 1 trial results for ovarian cancer drug By Investing.com - Investing.com South Africa

Apr 21, 2026

PERCEPTIVE ADVISORS LLC Expands Stake in Zymeworks Inc with Sign - GuruFocus

Apr 21, 2026

Zymeworks reports phase 1 trial results for ovarian cancer drug - Investing.com

Apr 21, 2026

Zymeworks (ZYME) Broadens ADC Toolkit at AACR 2026 Is Its Oncology Platform Taking Shape? - simplywall.st

Apr 21, 2026

Experimental Zymeworks cancer drug shows 61% response in ovarian study - Stock Titan

Apr 21, 2026

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data - BioSpace

Apr 21, 2026

Zymeworks Inc stock (US98985W1080): Is its bispecific antibody platform resilient enough for biotech - AD HOC NEWS

Apr 21, 2026

Apr 19, 2026

A Look At Zymeworks (ZYME) Valuation As AACR 2026 ADC Data Draws Investor Attention - Sahm

Apr 19, 2026

Apr 18, 2026

Zymeworks presents preclinical data on ADC pipeline at AACR By Investing.com - Investing.com Australia

Apr 18, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform - wahanariau.com

Apr 18, 2026

Apr 17, 2026

Zymeworks presents preclinical data on ADC pipeline at AACR - Investing.com

Apr 17, 2026

Zymeworks Inc. - Via Ritzau

Apr 17, 2026

Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN

Apr 17, 2026